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Summary Epidemic spread of methicillin-resistant Staphylococcus aureus (MRSA)
strains carrying the Staphylococcal Chromosomal Cassettes (SCC) mec type IV is
being increasingly reported in many geographical areas. A survey to determine the
prevalence and characteristics of MRSA SCCmec IV isolates identiﬁed in four general
hospitals in Palermo, Italy, was carried out. During the period February—June 2009,Molecular typing SCCmec type IVa has been found in 12 out of 94 isolates. Nine isolates from all
hospitals and all strains from a NICU outbreak occurring in the same period were
attributed with the ST22-IVa (EMRSA-15) clone. In our setting, due to the changing
MRSA epidemiology, detection of SCCmec IV could be poorly predictive of CA-MRSA.
© 2010 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
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IntroductionMethicillin-resistant Staphylococcus aureus (MRSA)
is the most commonly identiﬁed antibiotic-resistant
nosocomial pathogen worldwide [1]. According to
∗ Corresponding author at: Department of Sciences for Health
Promotion ‘‘G. D’Alessandro’’, University, via del Vespro 133,
I-90127 Palermo, Italy. Tel.: +39 0916553623.
E-mail address: diptigmi@unipa.it (C. Mammina).
1 See Appendix A.
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doi:10.1016/j.jiph.2010.09.004he most recent report of the European Antimicro-
ial Resistance Surveillance System (EARRS), MRSA
roportions among S. aureus isolates vary from
% in the northern to over 50% in southern Euro-
ean countries [2]. In Italy methicillin-resistant S.
ureus (MRSA) strains represent >40% of all hospital
cquired S. aureus infections, increasing up to 60%
n intensive care units (ICUs) [3].
Beginning in the late 1990s, there were many
eports of MRSA colonization and infection in
he community that involved patients without a
Sciences. Published by Elsevier Ltd. All rights reserved.
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aRSA ST22-IVa (EMRSA-15 clone) in Palermo, Italy
istory of recent contact with healthcare facilities
4]. Distinct community-associated MRSA (CA-
RSA) strains have been then identiﬁed, differing
rom their HA-MRSA counterparts by usually being
ore susceptible to non--lactam antibiotics and
arrying small Staphylococcal Chromosomal Cas-
ette (SCC) mec types, IV and V [5]. Moreover,
ertain S. aureus genotypes have been identiﬁed,
uch as the clonal group USA 300, sequence type
ST) 8 and EMRSA-15 (ST22), that more commonly
re recognized as a cause of human epidemic cases
f infections [6].
We carried out a survey to determine the
revalence and characteristics of MRSA SCCmec IV
solates identiﬁed among in- and outpatients by the
linical microbiology laboratories of four general
ospitals in Palermo, Italy.
aterials and methods
his study was conducted during the period
ebruary—June 2009 with the collaboration of four
linical microbiology hospital laboratories evenly
istributed in the city of Palermo, Italy. Partici-
ating laboratories performed isolation, conﬁrmed
ethicillin-resistance by their routine method
nd weekly sent their strains to the coordinat-
ng laboratory at the Department of Sciences for
ealth Promotion ‘‘G. D’Alessandro’’, University of
alermo, Italy. MRSA strains isolated from active
urveillance cultures performed in a NICU of one
f the participating hospitals were also collected.
At the coordinating laboratory, all isolates were
ubcultured, re-identiﬁed by biochemical tests and
oagulase production, submitted to antibiotic sus-
eptibility tests and stored at −70 ◦C.
Minimum inhibitory concentrations of van-
omycin, teicoplanin, daptomycin and tygecycline
ere determined by E-test, while suscep-
ibility to cefoxitin, cefepime, ceftriaxone,
hlaritromycin, chloramphenicol, ciproﬂoxacin,
lindamycin, eritromycin, gentamicin, imipenem,
ifampicin, tazobactam-piperacillin, tetracycline
nd trimethoprim/sulfamethoxazole was deter-
ined using the disk diffusion test. All assays
ere performed in accordance with Clinical and
aboratory Standards Institute guidelines [7].
taphylococcus aureus ATCC 25923 was included as
ontrol strains [7].
Presence of the mecA gene was investigatedy PCR using primers and conditions described
y Oliveira and de Lencastre [8]. Multiplex PCR
as performed to determine SCCmec types I to
[9]. Strains assigned to SCCmec type IVa were
ubmitted to polymerase chain reaction (PCR) for
o
p
s
S
t189
etection of the Panton-Valentine leukocidin toxin
enes lukS-PV and lukF-PV [10]. Multiple-locus
ariable-number tandem-repeat analysis (MLVA)
as performed according to Moser et al. [11] and
anding patterns visually compared and identiﬁed
y capital letters. Pulsed ﬁeld gel electrophore-
is (PFGE) was performed as described by Chung
t al. [12]. Multilocus sequence typing (MLST) was
erformed on the MRSA strains following the recom-
ended procedure at the S. aureus MLST website
http://saureus.mlst.net/misc/info.asp).
esults and discussion
verall, 94 consecutive isolates of MRSA isolated
rom 84 hospitalized and ambulatory patients were
ollected and sent to the coordinating laboratory
etween February 1st and June 30, 2009. During
he study period an outbreak of MRSA colonization
ccurred in the NICU under investigation. MRSA was
ultured from 12 newborn and ﬁve healthcare work-
rs.
SCCmec type IVa was found in 12 isolates identi-
ed from patients hospitalized in the four hospitals
nder study and in all MRSA isolates from the NICU.
ll strains, but one from a wound in the leg of a
atient with phlebitis, were PVL negative. Resis-
ance patterns are summarized in Table 1. Three
ifferent proﬁles were identiﬁed by MLST and ﬁve
y MLVA (Table 1 and Fig. 1). The predominant pro-
le was characterized by ST22 and MLVA type B.
FGE proﬁles of the ST22 strains were indistinguish-
ble for all strains, but two-strains id. 31 and 373
PVL positive) — that showed closely related pul-
otypes differing by one band only from the most
requently encountered proﬁle.
Emergence of type IV MRSA has been docu-
ented by several reports. In particular, the ST22
EMRSA-15) SCCmec IV clone is one of the pandemic
RSA clones and has been identiﬁed in several
ountries, including Italy [6]. In our study, this clone
as found to be widely disseminated, being respon-
ible also for an outbreak of colonization among
ewborn and healthcare workers in a NICU. Identiﬁ-
ation of a genetically closely related PVL-positive
T22 (EMRSA-15) strain is of further concern.
The preliminary results of our study show that
LVA was able to unequivocally identify the ST22
EMRSA-15) SCCmec IV clone and, hence, could be
simple and cost-effective typing tool in epidemi-
logical studies on MRSA. Moreover, according to a
revious report by Otter et al. [13], a ciproﬂoxacin
usceptible phenotype characterized all, but one,
T22 MRSA isolates. This further conﬁrms that cau-
ion should be applied when screening for MRSA
190 C. Bonura et al.
Table 1 Antibiotic resistance of the SCCmec IVa MRSA strains, February—June 2009, Palermo, Italy.
Strain id. Hospital Unit Clinical
specimen
Time of
isolation
Resistance
patterna
ST MLVA type
11 A ICU Bronchial
aspirate
February 20 CIP, TE 398 I
21 B ICU Bronchial
aspirate
March 13 CLR, TZP 1 P
26 C Neonatology Ocular swab March 11 TZP, TE 22 B
31 A Dermatology Wound swab April 7 GM, TZP, TE 22 B
32 C Internal
medicine
Mouth wash April 11 TZP, TE 22 B
43 C NICU Ocular swab April 28 TZP, TE 22 B
44 C Neonatology Umbilical
swab
April 23 TZP, TE 22 B
51 B Internal
medicine
Sputum May 4 TZP, TE 22 B
56 B Internal
medicine
Sputum June 4 TZP, TE 22 B
100 D Internal
medicine
Sputum April 8 CLR, IPM, TZP,
TE
1 V
437 D Infectious
diseases
Throat swab May 19 CLR, TZP, TE 22 B
373b D Vascular
diseases
Wound swab June 15 TZP, IPM 22 G
NICU outbreak
strain
TZP, TE 22 B
ICU, Intensive Care Unit; NICU, Neonatal Intensive Care Unit; ST, Sequence Type; MLVA, MultiLocus Variable-number tandem-repeat
M, im
e
p
tAnalysis.
a CIP, ciproﬂoxacin; CLR, chlaritromycin; GM, gentamicin; IP
b Panton-Valentine Leukocidin (PVL) positive strain.
by using ciproﬂoxacin-containing selective media.
Finally, as previously reported by other investiga-
tors [6,14], our ﬁndings imply that in the present
phase of changing epidemiology of MRSA in hospital
and community settings, antibiotic susceptibility
and/or detection of SCCmec IV could be poorly pre-
dictive of CA-MRSA. Epidemiological surveillance
studies investigating the molecular facies of MRSA
strains circulating in our geographic area are nec-
F
N
Figure 1 Multiple-locus variable-number tandem-repeat ana
Lanes: MW, ladder 100 bp; lanes 1—12, MRSA strains in the sam
from the NICU outbreak.ipenem; TZP, tazobactam-piperacillin; TE, tetracycline.
ssary to implement more targeted and effective
revention and control efforts and appropriate ini-
ial therapeutic approaches.unding
o funding sources.
lysis (MLVA) of the strains of ST22 (EMRSA-15) SCCmec IV.
e order as Table 1. Lanes 13—16, representative isolates
MC
N
E
N
A
A
o
I
b
P
e
S
S
e
R
A
P
o
P
M
e
(
D
o
R
[
[
[
[RSA ST22-IVa (EMRSA-15 clone) in Palermo, Italy
ompeting interests
one declared.
thical approval
ot required.
ppendix A. Appendix A
nna Maria D’Accardo (Laboratory of Microbiol-
gy, General Hospital ‘‘V. Cervello’’, Palermo,
taly), Rosa Lia Genco (Laboratory of Micro-
iology, General Hospital ‘‘Buccheri-La Ferla’’,
alermo, Italy), Ivana Guida (Department of Sci-
nces for Health Promotion ‘‘G. D’Alessandro’’,
ection of Hygiene, University of Palermo, Italy),
tella La Chiusa (Laboratory of Microbiology, Gen-
ral Hospital ‘‘Buccheri-La Ferla’’, Palermo, Italy),
achele Monastero (Laboratory of Microbiology,
RNAS, General Hospital ‘‘Civico e Benfratelli’’,
alermo, Italy), Gabriella Pecoraro (Laboratory
f Microbiology, General Hospital ‘‘V. Cervello’’,
alermo, Italy), Concetta Sodano (Laboratory of
icrobiology, ARNAS, General Hospital ‘‘Civico
Benfratelli’’, Palermo, Italy), Antonietta Vella
Department of Sciences for Health Promotion ‘‘G.
’Alessandro’’, Section of Microbiology, University
f Palermo, Italy).
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